Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapy

1. Genden EM, Sambur IM, de Almeida JR. Human papillomavirus and oropharyngeal squamous cell carcinoma: what the clinician should know. Eur Arch Otorhinolaryngol 2013; 270: 405-16.10.1007/s00405-012-2086-4Search in Google Scholar

2. Smid L, Lesnicar H, Zakotnik B, Soba E, Budihna M, Furlan L, et al. Radiotherapy, combined with simultaneous chemotherapy wit h mitomycin C and bleomycin for inoperable head and neck cancer - preliminary report. Int J Radiat Oncol Biol Phys 1995; 32: 769-75.10.1016/0360-3016(95)00525-4Search in Google Scholar

3. Budihna M, Šoba E, Šmid L, Zakotnik B, Strojan P, Čemažar M, et al. Inoperable oropharyngeal carcinoma treated with concomitant irradiation, mitomycin C and bleomycin - long term results. Neoplasma 2005; 52: 165-74.Search in Google Scholar

4. Fowler, JF. The linear quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1998; 62: 679-94.10.1259/0007-1285-62-740-679Search in Google Scholar

5. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958; 53: 457-89.10.1080/01621459.1958.10501452Search in Google Scholar

6. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.10.1038/bjc.1977.1Search in Google Scholar

7. Cox DR. Regression models and life tables. J Royal Stat Soc 1972; 34: 187-220.10.1111/j.2517-6161.1972.tb00899.xSearch in Google Scholar

8. Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. Radiol Oncol 2012; 46: 136-44.10.2478/v10019-012-0032-0Search in Google Scholar

9. Kudo Y, Takata T, Yasui W, Ogawa I, Miyauchi M, Takekoshi T, et al. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behaviour in oral squamous cell carcinoma. Cancer 1998; 83: 2447-55.10.1002/(SICI)1097-0142(19981215)83:12<2447::AID-CNCR7>3.0.CO;2-ASearch in Google Scholar

10. Shimada M, Kitagawa K, Dobashi Y, Isobe T, Hattori T, Uchida C, et al. High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers. Cancer Sci 2009; 100: 866-72.10.1111/j.1349-7006.2009.01122.xSearch in Google Scholar

11. Moreno-Galindo C, Hermsen M, García-Pedrero JM, Fresno MF, Suárez C, Rodrigo JP. p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncol 2014; 50: 128-34.10.1016/j.oraloncology.2013.10.018Search in Google Scholar

12. Fillies T, Woltering M, Brandt B, Van Diest JP, Werkmeister R, Joos U, et al. Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. Oncol Rep 2007; 17: 355-9.10.3892/or.17.2.355Search in Google Scholar

13. Zhang M, Li J, Wang L, Tian Z, Zhang P, Xu Q, et al. Prognostic significance of p21, p27 and survivin protein expression in patients with oral squamous cell carcinoma. Oncol Lett 2013; 6: 381-6.10.3892/ol.2013.1381Search in Google Scholar

14. O‘Rourke RW, Miller CW, Kato GJ, Simon KJ, Chen DL, Dang CV, et al. A potential transcriptional activation element in the p53 protein. Oncogene 1990; 5: 1829-32.Search in Google Scholar

15. Wu X, Zhong D, Lin B, Zhai W, Ding Z, Wu J. p38 MAPK regulates the expression of ether a go-go potassium channel in human osteosarcoma cells. Radiol Oncol 2013; 47: 42-9.10.2478/v10019-012-0043-xSearch in Google Scholar

16. Tandon S, Tudur-Smith C, Riley RD, Boyd MT, Jones TM. A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck. Cancer Epidemiol Biomarkers Prev 2010; 19: 574-87.10.1158/1055-9965.EPI-09-0981Search in Google Scholar

17. Awwad S, Jaros E, Somes J, Lunec J. P53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys 1996; 34: 323-32.10.1016/0360-3016(95)02108-6Search in Google Scholar

18. Grabenbauer GG, Muhlfriedel C, Roedel F, Niedobitek G, Hornung J, Roedel C, et al. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1041-50.10.1016/S0360-3016(00)00737-9Search in Google Scholar

19. Otero-Garcia J E, Youssef E, Enamorado I, Du W, Yoo G H, Merati K, et al. Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma Am J Otolaryngol 2004; 25: 231-9.Search in Google Scholar

20. Ribeiro DA, Nascimento FD, Fracalossi ACC, Gomes TS, Oshima CT, Franco MF. Expression profiling of cell cycle regulatory proteins in oropharyngeal carcinomas using tissue microarrays. In Vivo 2010; 24: 315-20.Search in Google Scholar

21. Erber R, Klein W, Andl T, Enders C, Born AI, Conradt C, et al. Aberrant p21 (CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer.1997; 74: 383-9.10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-RSearch in Google Scholar

22. Hafkamp HC, Mooren JJ, Claessen SM, Klingenberg B, Voogd AC, Bot FJ, et al. P21 Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis. Mod Pathol 2009; 22: 686-98.10.1038/modpathol.2009.23Search in Google Scholar

23. Chung YL, Lee MY, Horng C, Jian JJ, Cheng SH, Tsai SY, et al. Use of combined molecular biomarkers for prediction of clinical outcomes in locally advanced tonsillar cancers treated with chemoradiotherapy alone. Head Neck 2009; 3: 9-20.10.1002/hed.20913Search in Google Scholar

24. Perisanidis C, Perisanidis B, Wrba F, Brandstetter A, El Gazzar S, Papadogeorgakis N, et al. Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 2012; 41: 40-6.10.1111/j.1600-0714.2011.01071.xSearch in Google Scholar

25. Yu Z, Paul PM,. Haffty BG, Sasaki C, Zerillo C, Joe J, et al. Cyclin D1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 2005; 11: 1160-6.10.1158/1078-0432.1160.11.3Search in Google Scholar

26. Rahimi AS, Wilson DD, Saylor DK, Stelow EB, Thomas CY, Reibel JF, et al. p16, cyclin D1, and HIF-1α predict outcomes of patients with oropharyngeal squamous cell carcinoma treated with definitive intensity-modulated radiation therapy. Int J Otolaryngol. 2012 (2012); Article ID 685951, 9 p. doi: 10.1155/2012/685951.10.1155/2012/685951Search in Google Scholar

27. Koelbl O, Rosenwald A, Haberl M, Müller J, Reuther J, Flentje M. P53 and KI-67 as predictive markers for radiosensitivity in squamous cell carcinoma of the oral cavity. An immunohistochemical and clinicopathologic study. Int J Radiat Oncol Biol Phys 2001; 49: 147-54.10.1016/S0360-3016(00)01356-0Search in Google Scholar

28. Watanabe S, Watanabe R, Oton-Leite AF, Alencar Rde C, Oliveira JC, Leles CR, et al. Analysis of cell proliferation and pattern of invasion in oral squamous cell carcinoma. J Oral Sci 2010; 52: 417-24.10.2334/josnusd.52.41720881335Search in Google Scholar

29. Pereira CS, Oliveira MV, Fraga CA, Barros LO, Domingos PL, Roy A, et al. Impact of the epithelial dysplasia grading and Ki67 proliferation index in the adjacent non-malignant mucosa on recurrence and survival in head and neck squamous cell carcinoma. Pathol Res Pract 2012; 208: 651-6.10.1016/j.prp.2012.08.00222995634Search in Google Scholar

30. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6.Search in Google Scholar

31. Semrau R, Duerbaum H, Temming S, Huebbers C, Stenner M, Drebber U, et al. Prognostic impact of human papillomavirus status, survivin, and epidermal growth factor receptor expression on survival in patients treated with radiochemotherapy for very advanced nonresectable oropharyngeal cancer. Head Neck 2013; 35: 1339-44.10.1002/hed.2312623042483Search in Google Scholar

32. Ataman OU, Bentzen SM, Wilson GD, Daley FM, Richman PI, Saunders MI, et al. Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. Eur J Cancer 2004; 40: 2734-41.10.1016/j.ejca.2004.08.01915571955Search in Google Scholar

33. Chuang HC, Su CY, Huang HY, Chien CY, Chen CM, Huang CC. High Expression of CD105 as a prognostic predictor of early tongue cancer. Laryngoscope 2006; 116: 1175-9.10.1097/01.mlg.0000224338.56902.2816826056Search in Google Scholar

34. Foote RL, Weidner N, Harris J, Hammond E, Lewis JE, Vuong T, et al. Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505. Int J Radiat Oncol Biol Phys 2005; 61: 745-53.10.1016/j.ijrobp.2004.07.69415708253Search in Google Scholar

35. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.10.1056/NEJMoa0912217294376720530316Search in Google Scholar

36. Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, et al. Immune response during therapy with cisplatin of radiation for human papillomavirus related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009; 135: 1137-46.10.1001/archoto.2009.15919917928Search in Google Scholar